Lates News

On July 8th, the new drug Le Deqi Bai monoclonal antibody, a collaboration between XianSheng Pharmaceuticals and Conard Biopharmaceutical, was accepted by the National Medical Products Administration (NMPA) for a new drug application (NDA) for the treatment of atopic dermatitis. Le Deqi Bai monoclonal antibody is a fully human monoclonal antibody targeting IL-4R (IL-4R is a common subunit of IL-4 receptor and IL-13 receptor).